These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 34085900)
41. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine. Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM Hum Vaccin Immunother; 2016; 12(1):132-9. PubMed ID: 26575983 [TBL] [Abstract][Full Text] [Related]
42. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study. Knuf M; Romain O; Kindler K; Walther U; Tran PM; Pankow-Culot H; Fischbach T; Kieninger-Baum D; Bianco V; Baine Y; Miller J Eur J Pediatr; 2013 May; 172(5):601-12. PubMed ID: 23307281 [TBL] [Abstract][Full Text] [Related]
43. Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine. Khalil M; Al-Mazrou Y; Findlow H; Chadha H; Bosch Castells V; Johnson DR; Borrow R Clin Vaccine Immunol; 2012 Oct; 19(10):1561-6. PubMed ID: 22855388 [TBL] [Abstract][Full Text] [Related]
44. Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™). Croxtall JD; Dhillon S Drugs; 2012 Dec; 72(18):2407-30. PubMed ID: 23231026 [TBL] [Abstract][Full Text] [Related]
45. Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines. Serra L; Knuf M; Martinón-Torres F; Yi K; Findlow J Hum Vaccin Immunother; 2021 Jul; 17(7):2205-2215. PubMed ID: 33606596 [TBL] [Abstract][Full Text] [Related]
46. Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children. Klein NP; Baine Y; Kolhe D; Baccarini CI; Miller JM; Van der Wielen M Pediatr Infect Dis J; 2016 Jun; 35(6):662-72. PubMed ID: 26928521 [TBL] [Abstract][Full Text] [Related]
47. Safety and Immunogenicity of the Quadrivalent Meningococcal Serogroups A, C, W and Y Tetanus Toxoid Conjugate Vaccine Coadministered With Routine Childhood Vaccines in European Infants: An Open, Randomized Trial. Merino Arribas JM; Carmona Martínez A; Horn M; Perez Porcuna XM; Otero Reigada MD; Marès Bermúdez J; Centeno Malfaz F; Miranda M; Mendez M; Garcia Cabezas MA; Wittermann C; Bleckmann G; Fischbach T; Kolhe D; van der Wielen M; Baine Y Pediatr Infect Dis J; 2017 Apr; 36(4):e98-e107. PubMed ID: 28002359 [TBL] [Abstract][Full Text] [Related]
48. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D; Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207 [TBL] [Abstract][Full Text] [Related]
49. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. Pace D; Khatami A; McKenna J; Campbell D; Attard-Montalto S; Birks J; Voysey M; White C; Finn A; Macloed E; Faust SN; Kent AL; Heath PT; Borrow R; Snape MD; Pollard AJ BMJ; 2015 Apr; 350():h1554. PubMed ID: 25832102 [TBL] [Abstract][Full Text] [Related]
50. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents. Quiambao BP; Jain H; Bavdekar A; Dubey AP; Kolhe D; Bianco V; Van der Wielen M; Miller JM Hum Vaccin Immunother; 2016 Aug; 12(8):2162-2168. PubMed ID: 27152501 [TBL] [Abstract][Full Text] [Related]
51. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease. Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566 [TBL] [Abstract][Full Text] [Related]
52. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents. Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122 [TBL] [Abstract][Full Text] [Related]
53. Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children. Siberry GK; Warshaw MG; Williams PL; Spector SA; Decker MD; Jean-Philippe P; Yogev R; Heckman BE; Manzella A; Roa J; Nachman S; Lujan-Zilbermann J; Pediatr Infect Dis J; 2012 Jan; 31(1):47-52. PubMed ID: 21987006 [TBL] [Abstract][Full Text] [Related]
54. Persistence of bactericidal antibodies following primary and booster MenACWY-TT vaccination of toddlers: A review of clinical studies. Webber C; Peyrani P; Balmer P; Serra L Vaccine; 2020 Jun; 38(27):4236-4245. PubMed ID: 32389497 [TBL] [Abstract][Full Text] [Related]
55. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age. Ishola DA; Andrews N; Waight P; Yung CF; Southern J; Bai X; Findlow H; Matheson M; England A; Hallis B; Findlow J; Borrow R; Miller E Pediatr Infect Dis J; 2015 Aug; 34(8):865-74. PubMed ID: 26075813 [TBL] [Abstract][Full Text] [Related]
56. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study. Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785 [TBL] [Abstract][Full Text] [Related]
57. Antibody persistence and booster response 68 months after vaccination at 2-10 years of age with one dose of MenACWY-TT conjugate vaccine. Knuf M; Helm K; Kolhe D; Van Der Wielen M; Baine Y Vaccine; 2018 May; 36(23):3286-3295. PubMed ID: 29724511 [TBL] [Abstract][Full Text] [Related]
58. Safety and immunogenicity of a single dose of a quadrivalent meningococcal conjugate vaccine (MenACYW-D): a multicenter, blind-observer, randomized, phase III clinical trial in the Republic of Korea. Kim DS; Kim MJ; Cha SH; Kim HM; Kim JH; Kim KN; Lee JS; Choi JY; Castells VB; Kim HS; Bang J; Oster P Int J Infect Dis; 2016 Apr; 45():59-64. PubMed ID: 26921548 [TBL] [Abstract][Full Text] [Related]
59. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial. Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Findlow H; Borrow R; Booy R Vaccine; 2018 Jul; 36(29):4375-4382. PubMed ID: 29880243 [TBL] [Abstract][Full Text] [Related]
60. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-DT): a multicenter, open-label, non-randomized, phase III clinical trial. Yadav S; Manglani MV; Narayan DA; Sharma S; Ravish HS; Arora R; Castells VB; Arya S; Oster P Indian Pediatr; 2014 Jun; 51(6):451-6. PubMed ID: 24986280 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]